Announced details
Treatment of inflammatory diseases in cats, veterinary pharmaceuticals, animal health
In September 2025, Nippon Soda entered into a joint research agreement concerning novel monoclonal antibody drugs for dogs and cats. Under this announcement, Nippon Soda obtained a license to develop and market antibodies created by MabGenesis.
Head office: Yokohama, Kanagawa Prefecture; Representative Director: Shinjo Katsuhiro (新庄勝浩). A startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. It has the world's highest-quality phage display antibody library, the MOURA Library.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Antibodies for treating inflammatory diseases in cats, monoclonal antibody drugs for cats, MOURA Library (phage display antibody library) |
| Counterparty | MabGenesis株式会社 |
| Counterparty overview | Head office: Yokohama, Kanagawa Prefecture; Representative Director: Shinjo Katsuhiro (新庄勝浩). A startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. It has the world's highest-quality phage display antibody library, the MOURA Library. |
| Relationship with the Company | In September 2025, Nippon Soda entered into a joint research agreement concerning novel monoclonal antibody drugs for dogs and cats. Under this announcement, Nippon Soda obtained a license to develop and market antibodies created by MabGenesis. |
| Applicable area | Treatment of inflammatory diseases in cats, veterinary pharmaceuticals, animal health |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To apply the chemical and biochemical expertise cultivated through pesticide research and development in the animal health field, combine MabGenesis' antibody technology with Nippon Soda's expertise, and pursue early commercialization.